Navigation Links
CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS
Date:2/1/2011

MISSISSAUGA, Ontario, Feb.  1, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that CardioGenics and Merck Chimie SAS continue the commercialization process of CardioGenics' magnetic beads. Merck recently notified CardioGenics that while it is refining its encapsulation of the CardioGenics beads, it will also test a batch of magnetic beads coated with CardioGenics' proprietary silver-coating and polymer encapsulation processes (the "CardioGenics Encapsulated Beads") with the aim of commercializing the CardioGenics Encapsulated Beads while Merck Chimie is finalizing its owns proprietary encapsulation of the CardioGenics beads.

CardioGenics also announced that it is accelerating its commercialization efforts for its magnetic beads and as a result, the Company has signed two significant Material Transfer Agreements ("MTA") with 2 major international life sciences companies. Under the first MTA with one of the top 3 beads production and distribution companies, CardioGenics will furnish them with its silver-coated magnetic beads for polymer coating by the distributor. In addition, the distributor will provide CardioGenics with their magnetized bead prototypes, which CardioGenics will then silver-coat with its proprietary silver-coating technology.

Under the second MTA with one of the top IVD companies, CardioGenics will furnish them with its silver-coated and polymer encapsulated magnetic beads for subsequent testing and evaluation in their various test products.

Magnetic beads are a key component of virtually every immunoassay analyzer in the world. CardioGenics' proprietary silver-coating technology enhances the signaling properties of magnetic beads, resulting in an increased sensitivity of immunoassay analyzers by up to seven fold.  This can allow for more sophisticated data collection from patient samples being analyzed for the presence and progression of a disease– with no change to existing hardware or instrumentation. In addition to being used on CardioGenics' own beads, CardioGenics' proprietary silver coating can also be used on third-party magnetic beads to enhance their sensitivity.

Upon completion of the testing process, CardioGenics and the distributors will evaluate the test results and determine whether to further pursue commercialization of the resulting products. The Biosciences magnetic beads market is estimated to be in excess of $1.2 billion worldwide.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Raises $1.9 Million in Private Placement
2. CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
3. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
4. CardioGenics Featured on Canadas Business News Network
5. CardioGenics Holdings Inc. Receives New Ticker Symbol
6. CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer
7. New Corporate Profile Posted On CardioGenics Website
8. CardioGenics Announces Reverse Stock Split
9. CardioGenics Announces Update Regarding Status of Merck Agreement
10. CardioGenics to be Spotlighted in Three Publications During Month of April
11. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
Breaking Medicine News(10 mins):